Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis

Abstract 6-Sulfatoxymelatonin (aMT6s) is the main metabolite of melatonin in urine, and is a reliable surrogate biomarker reflecting the blood melatonin concentration. This meta-analysis assessed the association between urinary aMT6s level and BC incidence. The electronic databases PubMed, EMBASE, C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jing Xu, Lei Huang, Guo-Ping Sun
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bdb127d077a848609e1eccb41ca4558b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bdb127d077a848609e1eccb41ca4558b
record_format	dspace
spelling	oai:doaj.org-article:bdb127d077a848609e1eccb41ca4558b2021-12-02T16:08:11ZUrinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis10.1038/s41598-017-05752-92045-2322https://doaj.org/article/bdb127d077a848609e1eccb41ca4558b2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-05752-9https://doaj.org/toc/2045-2322Abstract 6-Sulfatoxymelatonin (aMT6s) is the main metabolite of melatonin in urine, and is a reliable surrogate biomarker reflecting the blood melatonin concentration. This meta-analysis assessed the association between urinary aMT6s level and BC incidence. The electronic databases PubMed, EMBASE, Cochrane Library, and Web of Science were searched. Risk ratios (RRs) were adopted to estimate the relative BC incidence. A total of 7 prospective case-control publications were included, and 6 of them were distinct studies. Pooled analysis of data from the 6 studies involving 1824 women with incident BC and 3954 matched control participants with no overlapping of subjects among studies indicated no significant association between the highest levels of urinary aMT6s and the incidence of BC (RR = 0.97, 95% CI, 0.88–1.08, P = 0.56). Negative associations were observed in postmenopausal women (RR = 0.88, 95% CI, 0.75–1.02, P = 0.10), estrogen receptor positive BC (RR = 0.83, 95% CI, 0.64–1.07, P = 0.15), and studies using 12-hour overnight urine (RR = 0.81, 95% CI, 0.61–1.07, P = 0.13), all with borderline significances. Lag time or invasive degree did not interfere with the results. There was no evident publication bias detected by the Egger’s test and the funnel plot. Conclusively, the current evidence did not support a significant association between urinary aMT6s level and BC risk.Jing XuLei HuangGuo-Ping SunNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jing Xu Lei Huang Guo-Ping Sun Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
description	Abstract 6-Sulfatoxymelatonin (aMT6s) is the main metabolite of melatonin in urine, and is a reliable surrogate biomarker reflecting the blood melatonin concentration. This meta-analysis assessed the association between urinary aMT6s level and BC incidence. The electronic databases PubMed, EMBASE, Cochrane Library, and Web of Science were searched. Risk ratios (RRs) were adopted to estimate the relative BC incidence. A total of 7 prospective case-control publications were included, and 6 of them were distinct studies. Pooled analysis of data from the 6 studies involving 1824 women with incident BC and 3954 matched control participants with no overlapping of subjects among studies indicated no significant association between the highest levels of urinary aMT6s and the incidence of BC (RR = 0.97, 95% CI, 0.88–1.08, P = 0.56). Negative associations were observed in postmenopausal women (RR = 0.88, 95% CI, 0.75–1.02, P = 0.10), estrogen receptor positive BC (RR = 0.83, 95% CI, 0.64–1.07, P = 0.15), and studies using 12-hour overnight urine (RR = 0.81, 95% CI, 0.61–1.07, P = 0.13), all with borderline significances. Lag time or invasive degree did not interfere with the results. There was no evident publication bias detected by the Egger’s test and the funnel plot. Conclusively, the current evidence did not support a significant association between urinary aMT6s level and BC risk.
format	article
author	Jing Xu Lei Huang Guo-Ping Sun
author_facet	Jing Xu Lei Huang Guo-Ping Sun
author_sort	Jing Xu
title	Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
title_short	Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
title_full	Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
title_fullStr	Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
title_full_unstemmed	Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
title_sort	urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/bdb127d077a848609e1eccb41ca4558b
work_keys_str_mv	AT jingxu urinary6sulfatoxymelatoninlevelandbreastcancerrisksystematicreviewandmetaanalysis AT leihuang urinary6sulfatoxymelatoninlevelandbreastcancerrisksystematicreviewandmetaanalysis AT guopingsun urinary6sulfatoxymelatoninlevelandbreastcancerrisksystematicreviewandmetaanalysis
_version_	1718384618925719552

Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis

Ejemplares similares